FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

Evidence for efficacy is based on the results from the PSMAddition study

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA Approves Pluvicto for PSMA+ Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	0	17.15	31-07-2026
2	FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer	0	18.14	16-09-2026
3	FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma	0	9.18	22-07-2026
4	FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally Advanced or metastatic breast cancer	0	14.91	09-09-2026
5	FDA approves groundbreaking new pancreatic cancer drug	0	7.77	26-08-2026
6	FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC	5	7	24-06-2026
7	В России начались клинические исследования препарата от рака предстательной железы	0	0	20-05-2021
8	STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class	0	4.23	14-08-2026
9	FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer	5	5	08-07-2026
10	FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer	0	16.54	22-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.79. Источник: www.esmo.org.

Найдите то, что Вас интересует